Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025Current HIV Research

A Randomized Controlled Trial Evaluating Virologic and Renal Outcomes After Switching from TDF+FTC or 3TC+EFV to TDF/3TC/DTG (TLD) Versus DTG+3TC in Virologically Suppressed Thai PWH – A Pilot Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSathaporn KanogtornMahasarakham UniversityOPOpass PutcharoenThai Red Cross SocietySPSamadhi PatamatamkulMahasarakham University

Discussion

Loading...

Member takes

Implication

Randomized trial reveals treatment impact on renal function in virologically suppressed PWH, suggesting DTG could be safer.

Key Points

  • Virologically suppressed patients showed a trend toward greater decline in eGFR when switched to TLD.
  • The mean difference in eGFR for TLD group was 5.15 mL/min/1.73 m² but not statistically significant (p = 0.532).
  • Switching from TDF+FTC or 3TC+EFV to either TLD or DTG+3TC was evaluated among 16 participants over 24 weeks.
  • These findings emphasize potential renal safety concerns, suggesting that DTG+3TC may be a better switch option.

Cite This Study

Kanogtorn et al. (2025) studied this question.

synapsesocial.com/papers/68de6f3183cbc991d0a21fb0https://doi.org/10.2174/011570162x384022250910065252
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical outcomes of switching to dolutegravir/lamivudine dual therapy in people living with HIV: A single‐centre retrospective study2025
  2. 2Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial2026
  3. 3P-353. Ten Years Results on the Effectiveness and Safety of DTG+3TC as a Switch Regimen in a Multicenter Cohort2026
  4. 4Renal outcomes with dolutegravir plus lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in ART-naive adults with HIV2026
  5. 5Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV ‐suppressed individuals: 48 weeks and beyond2026